## Management of Treatment-Resistant Mania on Lithium **Key Point:** When a patient on lithium monotherapy develops breakthrough mania despite therapeutic levels, augmentation with an anticonvulsant mood stabilizer (valproate or carbamazepine) is the evidence-based approach. **High-Yield:** Valproate (divalproex sodium) is the preferred augmentation agent because: - Rapid onset of action (days to 1–2 weeks) - Excellent efficacy in acute mania - Better tolerability profile than carbamazepine - No significant drug–drug interactions with lithium - Serum levels can be monitored (therapeutic range 50–100 μg/mL) ## Why Valproate Is Chosen Over Alternatives | Feature | Valproate | Carbamazepine | Fluoxetine | Chlorpromazine | |---------|-----------|---------------|-----------|----------------| | **Onset** | 1–2 weeks | 2–4 weeks | Worsens mania | Days | | **Efficacy in acute mania** | Excellent | Good | Contraindicated | Good (but antipsychotic) | | **Drug interactions** | Minimal with Li | Induces Li metabolism | Increases Li levels | Additive CNS effects | | **Role in bipolar** | Mood stabilizer | Mood stabilizer | Antidepressant (risky) | Acute agitation only | | **First-line augmentation** | **Yes** | Alternative | No | No | **Clinical Pearl:** SSRIs like fluoxetine are contraindicated in acute mania as they can precipitate or worsen manic episodes. Chlorpromazine, while useful for acute behavioral control, is an antipsychotic—not a mood stabilizer—and is not the drug of choice for maintenance augmentation. **Mnemonic:** **VACA** — **V**alproate is the **A**ugmentation **C**hoice for **A**cute mania on lithium. ## Mechanism of Valproate in Bipolar Disorder Valproate increases GABA synthesis and decreases GABA catabolism, enhancing GABAergic inhibition. It may also modulate protein kinase C and inositol metabolism, contributing to mood stabilization [cite:KD Tripathi 8e Ch 12].
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.